Updates in Detection and Management of BCRPC

Slides:

Advertisements

Similar presentations

This program will include a discussion of investigational agents not approved by the FDA for use in the United States, and data that were presented in.

Advertisements

Evolving Standards in HER2-Targeted Adjuvant Therapy for Breast Cancer

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Immunotherapies: Key Considerations in the Identification and Management of irAEs.

Evolving Paradigms in the Management of HR-Positive Breast Cancer

Improving Survival in Glioblastoma Multiforme

Advances in Managing Inhibitors in Patients With Hemophilia A

Applying New Data in Practice:

Progression After Cancer Immunotherapy in Advanced NSCLC

Standards of Care in Duchenne Muscular Dystrophy: A 2018 Update

New Standards of Care in ALK-Translocated Advanced NSCLC

Mid-Year Hemophilia Update

Induction Chemotherapy for Patients With High-Risk or Secondary AML

Determining the Best Treatment Algorithm for Patients With Head and Neck Cancer.

Differentiating Among the CDK 4/6 Inhibitors in the Management of Metastatic Breast Cancer.

The Resurgence of Topical Treatments Across a Spectrum of Psoriasis

Aligning Patients and Clinicians: Optimizing Outcomes in Metastatic NSCLC.

Expanding Treatment Horizons in Head and Neck Cancer: TRK Inhibitors

Emerging Targeted Agents for Relapsed/Refractory Non-Hodgkin Lymphoma

Addressing Disease Burden in Asthma

The Evolving Role of Immunotherapy in NSCLC

Optimizing Management of Advanced Bladder Cancer

Updates in Preventing Skeletal-Related Events in Multiple Myeloma

Individualizing Care in Ovarian Cancer

Addressing Challenges in Factor VIII Inhibitors in Children With Hemophilia.

Postpartum Depression

The Emerging Role of Immunotherapy in Hodgkin Lymphoma

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Next-Gen Psoriasis Therapies:

Evaluating Next-Generation BTK Inhibitors

Case Studies in Unresectable Hepatocellular Carcinoma

Hyperhidrosis Is Burdensome!

Essential Concepts in the Use of Immunotherapies in Bladder Cancer

Ask the Experts.

Immunotherapy for cSCC

Optimizing Frontline Care for Older Patients With Multiple Myeloma

How to Effectively Manage Patients With Cutaneous Squamous Cell Carcinoma.

New Data on Emerging Treatments for Psoriasis

How to Select Therapy In Newly Diagnosed CLL

Expert Insights Into the Latest Treatment of Advanced Soft-Tissue Sarcoma.

Personalizing Management in the Care of Patients With Advanced Sarcoma

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States and data.

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Expert Perspectives on the Clinical Use of Immune Reconstitution vs Escalation Therapy for MS.

Developments in the Wet AMD Treatment Landscape

Parkinson Disease Psychosis

Updates in the Management of Acute Promyelocytic Leukemia

Getting to Grips With the Science of CGRP and Migraine

Advances in Immunotherapy for Peanut Allergy

Immune Checkpoint Inhibitors in Lung Cancer

Locally Advanced Lung Cancer

Guide to Atopic Dermatitis

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Patient Questions and Expert Answers in Psoriasis:

Biomarker Testing: Harnessing All Sides of the Tumor Microenvironment

Evaluating BTK Inhibitors in CLL

All for One: Multidisciplinary Management in EGFR-Mutated NSCLC

Novel Concepts in the Management of RCC

Debates and Dilemmas, Part 1

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States, and data.

From Adjuvant to Metastatic in Melanoma

New Paradigms in M0 CRPC.

Optimizing Outcomes in mRCC: Finding the Balance of Immune Inhibition

This program will include a discussion of off-label treatment or use of investigational agents not approved by the FDA for use in the US, and data that.

Checkpoint Inhibitors in First-Line Advanced NSCLC

VKA Reversal and LVADs.

CDK4/6 Inhibitors.

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Immune Checkpoint Inhibitors in Lung Cancer

Presentation transcript:

Updates in Detection and Management of BCRPC

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal

BCRPC Overview

Defining BCRPC After RP

Defining BCRPC After RT

Case Patient Presentation

Case Patient PET Scans

Case Patient BCRPC Management

Pre-PET Clinical Implications of a Rising PSA

Pre-PET Diagnostic Evaluation of BCRPC

Advent of PC-Specific PET

NCCN PET Imaging Recommendations

18F-NaF-PET/CT Overview of an Older PET Tracer

ACR Guidelines for Detecting Recurrence

Choline Overview

11C-Choline PET/CT in Patients With BCRPC: Systematic Review

11C-Choline PET/CT Sensitivity by PSA Level

18F-Fluciclovine Overview

18F-Fluciclovine PET/CT in BCRPC BED-001 Study

18F-Fluciclovine PET/CT vs 11C-Choline PET/CT in BCRPC Prospective Trial

FALCON Trial Design

FALCON Trial Results

LOCATE Study Design and Detection Rates

LOCATE Study Change in Treatment

PSMA An Investigational PET Imaging Target

Example of 68Ga PSMA PET/CT

Bone Scintigraphy vs 18F-DCFPyL PET/CT

68Ga PSMA PET Analysis of 2 Trials

68Ga PSMA PET Analysis of 2 Trials (cont)

68Ga PSMA vs Choline

Challenges in Identifying PC Recurrence at Low PSA Levels

PET/MRI in Recurrent PC After RP

New Studies on PSMA From AUA 2018

Moving From Improved Visualization to Improved Outcomes

Conclusion

Abbreviations

Abbreviations (cont)